Immunotherapy with local radiation for lung cancer that has spread to a few sites

Trial details

Who runs it

Gustave Roussy, Cancer Campus, Grand Paris

Trial code

NCT06840782

Record updated

5 November 2026

Original description

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III studyRead full original descriptionShow less

First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients: a Randomized, Multicentre, Open-label Phase III Study

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Inclusion: Histologically proven advanced synchronous oligometastatic stage IV NSCLC; NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization; PDL1 status available; Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour; Maximum 5 metastases in 3 organs (EORTC criteria), according to brain MRI and FDG-PET; Symptomatic lesions requiring urgent palliative radiation, is permitted prior to randomization. These treated lesions should be counted towards the total number of metastases at the time of enrolment; Clinically required brain metastases (BM) ablation (surgery and/or SBRT) is permitted and BM count within the total number of 5 lesions. The patient would then be randomized to treatment of their extracranial disease; Acceptable organ function for RLT; ECOG performance status (PS) 0-1; Measurable lesions according to RECIST V1.1 on standard imaging; Patient aged 18 or more; Woman of childbearing potential must agree to use adequate contraception (implant type, vaginal ring, contraceptive pill, contraceptive patch, Intrauterine Device (IUD), etc.) for the duration of study participation and up to 6 months after completing treatment/therapy, in addition, male partners use a condom during this same period. Male patients must agree to use condom for the duration of study participation and up to 6 months after completing treatment/therapy; Patients affiliated to the social security system; Patient should understand, sign, and date the informed consent form written in French prior to any protocol-specific procedures performed; Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits, and examinations including follow-up.

Exclusion: Prior therapy with T-cell costimulation or immune checkpoint-targeted agents within 1 year; Uncontrolled concomitant (<1-year) malignancy except adequately treated basal or squamous cell carcinoma of the skin, or in-situ carcinoma of any organ or in-situ melanoma of the skin; Uncontrolled severe comorbidity, symptomatic interstitial lung disease or active infection; Non-squamous NSCLC with targetable tumour mutations and approved first line targeted therapy (such as EGFR, ALK and ROS1); Metastases not eligible to RLT: e.g. brainstem or diffuse serosal metastases (meningeal, pericardial, pleural, peritoneal, mesenteric) or that invades the gastrointestinal tract; Brain metastases only, without extra-cerebral metastases; Persons deprived of liberty by judicial or administrative decision; Persons subject to a legal protection measure (guardianship, curatorship, safeguard of justice); Persons not affiliated to a social security system or equivalent.

ClinicalTrials.gov NCT06840782